76 related articles for article (PubMed ID: 21708091)
1. Contact transcleral photodynamic cyclo-suppression in human eyes: a feasibility study.
Charisis SK; Detorakis ET; Vitanova VS; Panteleontidis VA; Kounis GA; Tsilimbaris MK
Can J Ophthalmol; 2011 Apr; 46(2):196-8. PubMed ID: 21708091
[TBL] [Abstract][Full Text] [Related]
2. Contact transscleral ciliary body photodynamic therapy in pigmented rabbits using verteporfin and diode laser: evaluation of treatment parameters.
Tsilimbaris MK; Charisis SK; Naoumidi T; Panteleontidis V; Skondra D; Christodoulakis E; Naoumidi I
Curr Eye Res; 2006; 31(7-8):577-85. PubMed ID: 16877266
[TBL] [Abstract][Full Text] [Related]
3. Contact transcleral ciliary body photodynamic therapy with verteporfin in pigmented rabbits: effect of repeated treatments.
Charisis SK; Naoumidi II; Ginis HS; Detorakis ET; Tsilimbaris MK
Photochem Photobiol; 2010; 86(1):194-9. PubMed ID: 19912560
[TBL] [Abstract][Full Text] [Related]
4. Investigating the effect of ciliary body photodynamic therapy in a glaucoma mouse model.
Matsubara A; Nakazawa T; Husain D; Iliaki E; Connolly E; Michaud NA; Gragoudas ES; Miller JW
Invest Ophthalmol Vis Sci; 2006 Jun; 47(6):2498-507. PubMed ID: 16723462
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic therapy with verteporfin for anterior segment neovascularizations in neovascular glaucoma.
Parodi MB; Iacono P
Am J Ophthalmol; 2004 Jul; 138(1):157-8. PubMed ID: 15234305
[TBL] [Abstract][Full Text] [Related]
6. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series.
Chan WM; Lam DS; Lai TY; Liu DT; Li KK; Yao Y; Wong TH
Ophthalmology; 2004 Aug; 111(8):1576-84. PubMed ID: 15288991
[TBL] [Abstract][Full Text] [Related]
7. Temporary intraocular pressure lowering by photodynamic therapy in pseudoexfoliation glaucoma.
Parodi MB; Iacono P; Bandello F
Ophthalmic Surg Lasers Imaging; 2011; 42(1):53-8. PubMed ID: 21117580
[TBL] [Abstract][Full Text] [Related]
8. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
[TBL] [Abstract][Full Text] [Related]
9. Photodynamic therapy with verteporfin for symptomatic circumscribed choroidal hemangioma: five-year outcomes.
Blasi MA; Tiberti AC; Scupola A; Balestrazzi A; Colangelo E; Valente P; Balestrazzi E
Ophthalmology; 2010 Aug; 117(8):1630-7. PubMed ID: 20417564
[TBL] [Abstract][Full Text] [Related]
10. Photodynamic therapy for neovascular glaucoma.
Battaglia Parodi M; Iacono P
Ophthalmology; 2005 Oct; 112(10):1844-5. PubMed ID: 16199270
[No Abstract] [Full Text] [Related]
11. [Clinical trial of verteporfin photodynamic therapy in Chinese age-related macular degeneration with subfoveal predominant choroidal neovascularization patients].
Chen YX; Ge J; Yan M; Jin CJ; Zhang MX; Dong FT; Lu F; Zhang CF; Zhao JL
Zhonghua Yan Ke Za Zhi; 2007 Mar; 43(3):198-205. PubMed ID: 17605900
[TBL] [Abstract][Full Text] [Related]
12. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration.
Augustin AJ; Schmidt-Erfurth U
Ophthalmology; 2006 Jan; 113(1):14-22. PubMed ID: 16360209
[TBL] [Abstract][Full Text] [Related]
13. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration.
Augustin AJ; Schmidt-Erfurth U
Am J Ophthalmol; 2006 Apr; 141(4):638-45. PubMed ID: 16564797
[TBL] [Abstract][Full Text] [Related]
14. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
[TBL] [Abstract][Full Text] [Related]
15. Effect of posterior juxtascleral triamcinolone acetonide on choroidal neovascular growth after photodynamic therapy with verteporfin.
Van de Moere A; Sandhu SS; Kak R; Mitchell KW; Talks SJ
Ophthalmology; 2005 Nov; 112(11):1896-903. PubMed ID: 16214216
[TBL] [Abstract][Full Text] [Related]
16. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial.
Chaudhary V; Mao A; Hooper PL; Sheidow TG
Ophthalmology; 2007 Dec; 114(12):2183-9. PubMed ID: 18054638
[TBL] [Abstract][Full Text] [Related]
17. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization.
Spaide RF; Sorenson J; Maranan L
Ophthalmology; 2003 Aug; 110(8):1517-25. PubMed ID: 12917166
[TBL] [Abstract][Full Text] [Related]
18. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up.
Lam DS; Chan WM; Liu DT; Fan DS; Lai WW; Chong KK
Br J Ophthalmol; 2004 Oct; 88(10):1315-9. PubMed ID: 15377558
[TBL] [Abstract][Full Text] [Related]
19. Verteporfin photodynamic therapy of choroidal neovascularization in angioid streaks: one-year results of a prospective case series.
Browning AC; Chung AK; Ghanchi F; Harding SP; Musadiq M; Talks SJ; Yang YC; Amoaku WM;
Ophthalmology; 2005 Jul; 112(7):1227-31. PubMed ID: 15921757
[TBL] [Abstract][Full Text] [Related]
20. Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration.
Ergun E; Maár N; Ansari-Shahrezaei S; Wimpissinger B; Krepler K; Wedrich A; Stur M
Am J Ophthalmol; 2006 Jul; 142(1):10-16. PubMed ID: 16815246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
